Hexima News and Investor Updates

Hexima receives approval to conduct a phase 1/2a study for fungal nail infections

Hexima Limited is pleased to announce today that it has received Human Research Ethics Committee approval to conduct a phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Obtaining ethics approval for our first clinical trial is a major milestone for Hexima. It is the culmination of the last three years of work to generate the required non-clinical data including preclinical safety/toxicology, efficacy testing and manufacture, formulation and stability of HXP124. The ethics committee has reviewed this data, along with our clinical study design, and granted us permission to test this molecule on human patients for the first time. This is a critical step forward in the development of HXP124 as a treatment for fungal nail infections and we are very excited to begin this next phase of development.”

read more

Shareholder Update: Q1 2017

Shareholders are invited to attend a presentation by Hexima CEO Dr Nicole van der Weerden. To view a copy of the presentation click here.

Upcoming Event: Tuesday 25th July at 11.30am at Lvl 38, 88 Phillip Street Sydney (offices of Bell Potter).

read more

Hexima Shareholder Update and Share Trading

Hexima is pleased to advise that it has completed a pivotal GLP repeat-dose dermal irritation study in minipigs for HPX124 which should provide sufficient pre-clinical animal toxicology data to support a first-in-human clinical trial for HXP124 as a treatment of onychomycosis. Further details are provided in the presentation.

read more

Hexima Rights Issue – Completed

Dear Shareholders I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%.  This result was very encouraging and Hexima is grateful to all shareholders who...

read more

Extension of Hexima’s rights issue offer

Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...

read more